- Home
- AGL vs IVA Comparison
AGL vs IVA Comparison
Compare AGL & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- IVA
- Stock Information
- Founded
- AGL 2016
- IVA 2011
- Country
- AGL United States
- IVA France
- Employees
- AGL N/A
- IVA N/A
- Industry
- AGL Managed Health Care
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- IVA Health Care
- Exchange
- AGL Nasdaq
- IVA Nasdaq
- Market Cap
- AGL 952.1M
- IVA 769.0M
- IPO Year
- AGL 2021
- IVA 2020
- Fundamental
- Price
- AGL $1.07
- IVA $5.46
- Analyst Decision
- AGL Hold
- IVA Strong Buy
- Analyst Count
- AGL 20
- IVA 6
- Target Price
- AGL $3.03
- IVA $15.33
- AVG Volume (30 Days)
- AGL 7.3M
- IVA 71.5K
- Earning Date
- AGL 11-06-2025
- IVA 09-26-2025
- Dividend Yield
- AGL N/A
- IVA N/A
- EPS Growth
- AGL N/A
- IVA N/A
- EPS
- AGL N/A
- IVA N/A
- Revenue
- AGL $5,901,182,000.00
- IVA $14,591,573.00
- Revenue This Year
- AGL N/A
- IVA $80.35
- Revenue Next Year
- AGL $7.04
- IVA N/A
- P/E Ratio
- AGL N/A
- IVA N/A
- Revenue Growth
- AGL 11.76
- IVA N/A
- 52 Week Low
- AGL $0.71
- IVA $1.53
- 52 Week High
- AGL $6.08
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- AGL 35.39
- IVA 58.24
- Support Level
- AGL $1.03
- IVA $5.21
- Resistance Level
- AGL $1.29
- IVA $5.78
- Average True Range (ATR)
- AGL 0.09
- IVA 0.35
- MACD
- AGL 0.01
- IVA -0.03
- Stochastic Oscillator
- AGL 10.00
- IVA 47.09
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.